News Medical

ECOG-ACRIN and Caris Life Sciences launch collaborative cancer research initiative

ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences ® (Caris) announced today a multi-year research collaboration wherein Caris is pairing its highly sophisticated and comprehensive ...
Nasdaq

ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer

WALTHAM, Mass., May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN ...
ascopubs.org

Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors

Effect of Early Palliative Care on End-of-Life Health Care Costs: A Population-Based, Propensity Score–Matched Cohort Study We retrospectively identified patients with advanced solid tumors who were ...
EurekAlert!

ECOG-ACRIN research at ASCO 2020

Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of research findings at the annual meeting of the American Society of Clinical Oncology (ASCO), occurring virtually May ...
News Medical

ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy. The ...